Biomolecules & Therapeutics

  • 제33권1호
  • /
  • Pages.143-154
  • /
  • 2025
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Taurine Synthesis by 2-Aminoethanethiol Dioxygenase as a Vulnerable Metabolic Alteration in Pancreatic Cancer

  • Hoonsik Nam (Natural Products Research Institute, College of Pharmacy, Seoul National University) ;
  • Woohyung Lee (Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Yun Ji Lee (Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University) ;
  • Jin-Mo Kim (Natural Products Research Institute, College of Pharmacy, Seoul National University) ;
  • Kyung Hee Jung (Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University) ;
  • Soon-Sun Hong (Department of Biomedical Sciences, College of Medicine, and Program in Biomedical Science & Engineering, Inha University) ;
  • Song Cheol Kim (Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center) ;
  • Sunghyouk Park (Natural Products Research Institute, College of Pharmacy, Seoul National University)
  • 투고 : 2024.05.27
  • 심사 : 2024.06.26
  • 발행 : 2025.01.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Pancreatic ductal adenocarcinoma (PDAC) exhibits an altered metabolic profile compared to normal pancreatic tissue. However, studies on actual pancreatic tissues are limited. Untargeted metabolomics analysis was conducted on 54 pairs of tumor and matched normal tissues. Taurine levels were validated via immunohistochemistry (IHC) on separate PDAC and normal tissues. Bioinformatics analysis of transcriptomics and proteomics data evaluated genes associated with taurine metabolism. Identified taurine-associated gene was validated through gene modulation. Clinical implications were evaluated using patient data. Metabolomics analysis showed a 2.51-fold increase in taurine in PDAC compared to normal tissues (n=54). IHC confirmed this in independent samples (n=99 PDAC, 19 normal). Bioinformatics identified 2-aminoethanethiol dioxygenase (ADO) as a key gene modulating taurine metabolism. IHC on a tissue microarray (39 PDAC, 10 normal) confirmed elevated ADO in PDAC. The ADO-Taurine axis correlated with PDAC recurrence and disease-free survival. ADO knockdown reduced cancer cell proliferation and tumor growth in a mouse xenograft model. The MEK-related signaling pathway is suggested to be modulated by ADO-Taurine metabolism. Our multi-omics investigation revealed elevated taurine synthesis mediated by ADO upregulation in PDAC. The ADO-Taurine axis may serve as a biomarker for PDAC prognosis and a therapeutic target.

키워드

과제정보

This work was supported by the National Research Foundation (NRF) grant funded by the Korean government (NRF-2021R1A5A2031612 to S-S.H.), a grant (2021IP0020-1 to S.C.K.) from Asan Institute for Life Sciences, Asan Medical Center, and a Inha University Grant (to K.H.J).

참고문헌

  1. Battini, S., Faitot, F., Imperiale, A., Cicek, A., Heimburger, C., Averous, G., Bachellier, P. and Namer, l. (2017) Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients. BMC Med. 15, 56.
  2. Bauer, T. M., EI-Rayes, B. F., Li, X., Hammad, N., Philip, P. A., Shields, A. F., Zalupski, M. M. and Bekaii-Saab, T. (2013) Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 119, 285-292.
  3. Boyd, L. N., Ali, M., Puik, J. R., Meijer, L. L., Le Large, T. Y., van Laarhoven, H. W., Giovannetti, E. and Kazemier, G. (2023) hENT1 as a predictive biomarker in PDAC. Clini. Cancer Res. 29, 2944.
  4. Chandrashekar, D. S., Karthikeyan, S. K., Korla, P. K., Patel, H., Shovon, A. R., Athar, M., Netto, G. J., Qin, Z. S., Kumar, S. and Manne, U. (2022) UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18-27.
  5. Chen, Y., Wang, C., Song, J., Xu, R., Ruze, R. and Zhao, Y. (2021) S100A2 is a prognostic biomarker involved in immune infiltration and predict immunotherapy response in pancreatic cancer. Front. Immunol. 12, 758004.
  6. Cheong, J.-H., Wang, S. C., Park, S., Porembka, M. R., Christie, A. L., Kim, H., Kim, H. S., Zhu, H., Hyung, W. J. and Noh, S. H. (2022) Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nat. Commun. 13, 774.
  7. Chun, Y. S., Pawlik, T. M. and Vauthey, J.-N. (2018) 8th Edition of the AJCC Cancer Staging Manual: pancreas and hepatobiliary cancers. Ann. Surg. Oncol. 25, 845-847.
  8. Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., Charles, R.-P., Rabinovich, B. A., Hann, B. and Dankort, D. (2012) A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2, 685-693.
  9. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S. and de Ia Fouchardière, C. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825.
  10. Dominy, J. E., Simmons, C. R., Hirschberger, L. L., Hwang, J., Coloso, R. M. and Stipanuk, M. H. (2007) Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase. J. Biol. Chem. 282, 25189-25198.
  11. El Agouza, I., Eissa, S., 티 Houseini, M., EI-Nashar, D. E. and Abd티 Hameed, O. (2011) Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients. Angiogenesis 14, 321-330.
  12. Encarnación-Rosado, J. and Kimmelman, A. C. (2021) Harnessing metabolic dependencies in pancreatic cancers. Nat. Rev. Gastroenterol. Hepatol. 18, 482-492.
  13. Gao, P., Yang, C., Nesvick, C. L., Feldman, M. J., Sizdahkhani, S., Liu, H., Chu, H., Yang, F., Tang, L. and Tian, J. (2016) Hypotaurine evokes a malignant phenotype in glioma through aberrant hypoxic signaling. Oncotarget 7, 15200.
  14. Grove, R. Q. and Karpowicz, S. J. (2017) Reaction of hypotaurine or taurine with superoxide produces the organic peroxysulfonic acid peroxytaurine. Free. Radic. Biol. Med. 108, 575-584.
  15. Guo, S., Fesler, A., Wang, H. and Ju, J. (2018) microRNAbased prognostic biomarkers in pancreatic cancer. Biomarker Res. 6, 18.
  16. He, F., Ma, N., Midorikawa, K., Hiraku, Y., Oikawa, S., Zhang, Z., Huang, G., Takeuchi, K. and Murata, M. (2018) Taurine exhibits an apoptosis inducing effect on human nasopharyngeal carcinoma cells through PTEN/Akt pathways in vitro. Amino Acids 50, 1749-1758.
  17. Hristova, V. A. and Chan, D. W. (2019) Cancer biomarker discovery and translation: proteomics and beyond. Expert Rev. Proteomics 16, 93-103.
  18. Kamphorst, J. J., Nofal, M., Commisso, C., Hackett, S. R., Lu, W., Grabocka, E., Van der Heiden, M. G., Miller, G., Drebin, J. A. and Bar-Sagi, D. (2015) Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544-553.
  19. Kanehisa, M. and Goto, S. (2000) KEGG: kyo to encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30.
  20. Kaur, P., Sheikh, K., Kirilyuk, A., Kirilyuk, K., Singh, R., Ressom, H. W. and Cheema, A. K. (2012) Metabolomic profiling for biomarker discovery in pancreatic cancer. Int. J. Mass Spectrom. 310, 44-51.
  21. Kim, J., Bamlet, W. R., Oberg, A. L., Chaffee, K. G., Donahue, G., Cao, X.-J., Chari, S., Garcia, B. A., Petersen, G. M. and Zaret, K. S. (2017) Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci. Transl. Med. 9, eaah5583.
  22. Kim, Y., Yeo, I. Huh, I., Kim, J., Han, D., Jang, J.-Y. and Kim, Y. (2021) Development and multiple validation of the protein multi-marker panel for diagnosis of pancreatic cancer. Clin. Cancer Res. 27, 2236-2245.
  23. Li, H., Ruan, W.-J., Liu, L.-Q., Wan, H.-F., Yang, X.-H., Zhu, W.-F., Yu, L.-H., Zhang, X.-L. and Wan, F.-S. (2019) Impact of Taurine on the proliferation and apoptosis of human cervical carcinoma cells and its mechanism. Chin. Med. J. 132, 948-956.
  24. Li, J., Liu, D., Hua, R., Zhang, J., Liu, W., Huo, Y., Cheng, Y., Hong, J. and Sun, Y. (2014) Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and IncRNA BC008363 an independent prognostic factor in PDAC. Pancreatology 14, 385-390.
  25. Li, Q., Yang, G., Feng, M., Zheng, S., Cao, Z., Qiu, J., You, L., Zheng, L., Hu, Y. and Zhang, T. (2018) NF-κB in pancreatic cancer: its key role in chemoresistance. Cancer Lett. 421, 127-134.
  26. Li, Y., Peng, Q., Shang, J., Dong, W., Wu, S., Guo, X., Xie, Z. and Chen, C. (2023) The role of taurine in male reproduction: physiology, pathology and toxicology. Front. Endocrinol. (Lausanne) 14, 1017886.
  27. Lourenco, R. and Camilo, M. (2002) Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr. Hosp. 17, 262-270.
  28. Ma, N., He, F., Kawanokuchi, J., Wang, G. and Yamashita, T. (2022) Taurine and its anticancer functions: in VIVO and in vitro study. Adv. Exp. Med. Biol. 1370, 121-128.
  29. Masson, N., Keeley, T. P., Giuntoli, B., White, M. D., Puerta, M. L., Perata, P., Hopkinson, R. J., Flashman, E., Licausi, F. and Ratcliffe, P. J. (2019) Conserved N-terminal cysteine dioxygenases transduce responses to hypoxia in animals and plants. Science 365, 65-69.
  30. Mayerle, J., Kalthoff, H., Reszka, R., Kamlage, B., Peter, E., Schniewind, B., Maldonado, S. G., Pilarsky, C., Heidecke, C.-D. and Schatz, P. (2018) Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut 67, 128-137.
  31. Nam, H., Hong, S.-S., Jung, K. H., Kang, S., Park, M. S., Kang, S., Kim, H. S., Mai, V.-H., Kim, J. and Lee, H. (2022) A serum marker for early pancreatic cancer with a possible link to diabetes. J. Natl. Cancer Inst. 114, 228-234.
  32. Oh, S., Jo, S., Bajzikova, M., Kim, H. S., Dao, T. T., Rohlena, J., Kim, J.-M., Neuzil, J. and Park, S. (2023) Non-bioenergetic roles of mitochondrial GPD2 promote tumor progression. Theranostics 13, 438.
  33. Ozkan-Dagliyan, l., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz-Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P. and Pierobon, M. (2020) Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers. Cell Rep. 31, 107764.
  34. Park, W., Chawla, A. and O'Reilly, E. M. (2021) Pancreatic cancer: a review. JAMA 326, 851-862.
  35. Pedersen, K., Bilal, F., Bernado Morales, C., Salcedo, M., Macarulla, T., Massó-Vallés, D., Mohan, V., Vivancos, A., Carreras, M. and Serres, X. (2017) Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene 36, 5639-5647.
  36. Ripps, H. and Shen, W. (2012) taurine: a "very essential" amino acid. Mol. Vis. 18, 2673.
  37. Roa-Peña, L., Leiton, C. V., Babu, S., Pan, C.-H., Vanner, E. A., Akalin, A., Bandovic, J., Moffitt, R. A., Shroyer, K. R. and Escobar-Hoyos, L. F. (2019) Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer. Sci. Rep. 9, 11239.
  38. Shen, D., Tian, L., Yang, F., Li, J. Li, X., Yao, Y., Lam, E. W.-F., Gao, P., Jin, B. and Wang, R. (2021) ADO/hypotaurine: a novel metabolic pathway contributing to glioblastoma development. Cell Death Discov. 7, 21.
  39. Singh, P., Gollapalli, K., Mangiola, S., Schranner, D., Yusuf, M. A., Chamoli, M., Shi, S. L., Lopes Bastos, B., Nair, T. and Riermeier, A. (2023) Taurine deficiency as a driver of aging. Science 380, eabn9257.
  40. Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C. and Kimmelman, A. C. (2013) Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105.
  41. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global cancer statistics 2020: GLO-BOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209-249.
  42. Suzuki, T., Otsuka, M., Seimiya, T., lwata, T., Kishikawa, T. and Koike, K. (2020) The biological role of metabolic reprogramming in pancreatic cancer. MedComm 1, 302-310.
  43. Tang, Z., Li, C., Kang, B., Gao, G., Li, C. and Zhang, Z. (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98-W102.
  44. Tu, S., Zhang, X. L., Wan, H. F., Xia, Y Q., Liu, Z. Q., Yang, X. H. and Wan, F. S. (2018) Effect of taurine on cell proliferation and apoptosis human lung cancer A549 cells. Oncol. Lett. 15, 5473-5480.
  45. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W. and Saleh, M. N. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703.
  46. Wang, A. S., Lodi, A., Rivera, L. B., Izquierdo-Garcia, J. L., Firpo, M. A., Mulvihill, S. J., Tempero, M. A., Bergers, G. and Ronen, S. M. (2014) HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 27, 1361-1370.
  47. Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M. and Del'Antonio, G. (2011) Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25, 717-729.
  48. Yang, Z., LaRiviere, M. J., Ko, J., Till, J. E., Christensen, T., Yee, S. S., Black, T. A., Tien, K., Lin, A. and Shen, H. (2020) A multianalyte panel consisting of extracellular vesicle miRNAs and mRNAs, cfDNA, and CA19-9 shows utility for diagnosis and staging of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 26, 3248-3258.
  49. Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H. and Coloff, J. L. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670.
  50. Zhang, X., Tu, S., Wang, Y., Xu, B. and Wan, F. (2014) Mechanism of taurine-induced apoptosis in human colon cancer cells. Acta Biochim. Biophys. Sin. 46, 261-272.